CARLSBAD, Calif., Jan. 8 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals,
Inc. (Nasdaq: ISIS) announced that the Company will present at the 27th Annual
J.P. Morgan Healthcare Conference in San Francisco, CA. Stanley T. Crooke,
M.D., Ph.D., Chairman and CEO of Isis, will provide an overview of the Company
and an update on recent clinical and business activities.
The presentation will begin at 11:30 a.m. PT (2:30 p.m. ET) on Monday,
January 12, 2009. To access the live audio webcast, log on to
www.isispharm.com. In addition to the live webcast, the presentation will be
archived for a limited time on the Company's Web site.
About Isis Pharmaceuticals, Inc.
Isis is exploiting its expertise in RNA to discover and develop novel
drugs for its product pipeline and for its partners. The Company has
successfully commercialized the world's first antisense drug and has 19 drugs
in development. Isis' drug development programs are focused on treating
cardiovascular and metabolic diseases. Isis' partners are developing
antisense drugs invented by Isis to treat a wide variety of diseases. Isis is
a joint owner of Regulus Therapeutics Inc., a joint venture focused on the
discovery, development and commercialization of microRNA therapeutics. Isis
also has made significant innovations beyond human therapeutics resulting in
products that other companies, including Abbott, are commercializing. As an
innovator in RNA-based drug discovery and development, Isis is the owner or
exclusive licensee of over 1,600 issued patents worldwide. Additional
information about Isis is available at www.isispharm.com.
This press release includes forward-looking statements regarding Isis
Pharmaceuticals' business, the financial position and outlook for Isis as well
as its Regulus joint venture, and the therapeutic and commercial potential of
the Company's technologies and products in development. Any statement
describing Isis' goals, expectations, financial or other projections,
intentions or beliefs is a forward-looking statement and should be considered
an at-risk statement, including those statements that are described as Isis'
goals. Such statements are subject to certain risks and uncertainties,
particularly those inherent in the process of discovering, developing and
commercializing drugs that are safe and effective for use as human
therapeutics, and in the endeavor of building a business around such products.
Isis' forward-looking statements also involve assumptions that, if they never
materialize or prove correct, could cause its results to differ materially
from those expressed or implied by such forward-looking statements. Although
Isis' forward-looking statements reflect the good faith judgment of its
management, these statements are based only on facts and factors currently
known by Isis. As a result, you are cautioned not to rely on these
forward-looking statements. These and other risks concerning Isis' programs
are described in additional detail in Isis' annual report on Form 10-K for the
year ended December 31, 2007, and its most recent quarterly report on Form
10-Q, which are on file with the SEC. Copies of these and other documents are
available from the Company.
In this press release, unless the context requires otherwise, "Isis,"
"Company," "we," "our," and "us" refers to Isis Pharmaceuticals and its
subsidiaries and joint venture.
Isis Pharmaceuticals is a registered trademark of Isis Pharmaceuticals,
Inc. Regulus Therapeutics is a trademark of Regulus Therapeutics Inc.
SOURCE Isis Pharmaceuticals, Inc.
-0- 01/08/2009
/CONTACT: Kristina Lemonidis, Director, Corporate Communications,
+1-760-603-2490, or Amy Blackley, Ph.D., Manager, Corporate Communications,
+1-760-603-2772, both of Isis Pharmaceuticals, Inc./
/Web Site: http://www.isispharm.com /
(ISIS)
CO: Isis Pharmaceuticals, Inc.
ST: California
IN: HEA MTC PHA
SU: TDS
PR
-- LA56713 --
9863 01/08/2009 07:00 EST http://www.prnewswire.com
